

Ref: MHL/Sec&Legal/2020-21/151

Date: November 11, 2020

To,  
**Head, Listing Compliance Department**  
**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai - 400 001.

**Scrip Code: 542650**

**Head Listing Compliance Department**  
**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051.

**Scrip Symbol: METROPOLIS**

**Sub: Intimation of Press Release**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith a Press Release as mentioned below:

'Metropolis Healthcare Ltd records 29% growth in Revenue; EBITDA Margin expands by 470 bps YoY to 32.9%'

You are requested to take the above information on record.

Thanking You,

Yours Faithfully,  
For **Metropolis Healthcare Limited**



Poonam Tanwani  
**Company Secretary and Compliance Officer**  
Membership No.: ACS 19182

Encl. a/a

**BLOOD TESTS • DIAGNOSTICS • WELLNESS**

**METROPOLIS**  
The Pathology Specialist

**Metropolis Healthcare Limited**

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.  
CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: [support@metropolisindia.com](mailto:support@metropolisindia.com)  
Website: [www.metropolisindia.com](http://www.metropolisindia.com)  
Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

## Metropolis Healthcare Ltd records 29% growth in Revenue; EBITDA Margin expands by 470 bps YoY to 32.9%

*Continued traction in Non-COVID testing, sustained cost optimization efforts has led to record revenue & profitability in Q2FY21*

- Conducted 4.83 Million Tests from 2.62 Million Patient Visits
- 29.2% YoY revenue growth, industry leading performance
- Share of B2C Business in Focus Cities at 60% in Q2FY21 (Non-COVID revenue), in-line with our plan to achieve 65% B2C contribution in focus cities in coming years
- With scale-up of Non-Covid business, cost management measures as well as operating leverage on-account of significant uptick in Revenue, the EBITDA margins came in at record levels

**Mumbai, November 11, 2020:** Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its unaudited consolidated financial results today for the second quarter (Q2FY21).

### Financial Highlights

**INR. 289 cr**

+29.2%YoY

**Revenue**

**59.7%**

+440 bps YoY  
Revenue Share of B2C in Focus  
Cities (Non-Covid)

**4.83 Mn**

**No. of Tests**

*Happy with yet another strong industry-leading performance and results with overall revenues growing over 29% on YoY basis. Scale up in Non-COVID tests along with a focus on cost optimization has helped us achieve record EBDITA margin at 32.9%.*

*Metropolis has conducted the maximum number of COVID tests in Q2FY21 in the industry. We are well placed with strong financial fundamentals and further ramp up of home tests and non-COVID tests is expected in H2FY21. In line with our expansion and growth plans, we will continue our lookout towards potential mergers and acquisition in H2.*

**Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Ltd**

## MEDIA RELEASE

### GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

### AWARDS AND ACCOLADES

Our MD, Ms. Ameera Shah won the Leader of the Year Award by CNBC-AWAAZ CEO Award

Metropolis won the Most Admired Healthcare Company of the Year and our CEO, Mr. Vijender Singh won the "Best Business Leader of the Year" award at Business Leader of the Year Awards, 2020

Metropolis won the award for Best IT Practices at the Data Center Summit, 2019

Metropolis won the 'Best Logistics Network Optimization' & 'Best use of Technology in Logistics' awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai.

Our Chairman, Dr. Sushil Shah, won the 'Lifetime Achievement Award' at the South Asia Pacific Healthcare Summit & Business Awards, 2019 for his immense contribution to the diagnostic industry.

Our MD, Ms. Ameera Shah won the 'Best Woman Entrepreneur of the Year' in Healthcare Sector award at the ASSOCHAM Women Leadership Awards

Metropolis won the Patient Experience team of the Year Award at PEXA Awards 2019 in Delhi

## FINANCIAL HIGHLIGHTS

In INR Crs	Q2FY21	Q2FY20
Revenue from Operations	288.6	223.3
EBIDTA (before CSR & ESOP)	95.0	63.0
EBIDTA (before CSR & ESOP) (%)	32.9%	28.2%
Profit After Tax	60.5	43.1
Profit After Tax (%)	21.0%	19.3%

**About Metropolis:** Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

### Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

### For further details please contact:

#### Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Ms. Nadhiya Mali – Lead, Corporate Communications  
nadhiya.mali@metropolisindia.com +91-8879009517  
www.metropolisindia.com

### **SGA** Strategic Growth Advisors

#### Investor Relations Advisors: Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net /  
sagar.shroff@sgapl.net +91-77383 77756